Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 17;55(12):2436–2453.e5. doi: 10.1016/j.immuni.2022.11.007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Relationship between plasma actin, ORM proteins, and infection outcomes

Analysis of 465 samples from 63 CP with maximum WHO-7.

(A) Daily cumulative average relative to time post-admission for actin (ACTB;ACTG1), ORM1;ORM2, HI, and CRP separated by outcome: survivors (gray) or deceased (red). Right: Daily cumulative average FGG in individuals with (TE+ red) or without thromboembolism (TE− gray).

(B) Change in NETase activity over time in 44 CP samples (left). NETase activity in early and late samples connected by a line and the corresponding paired Wilcoxon test for the difference per participant (right).

(C) DNase activity (D₅₀) values obtained from CP samples segregated by 0–30 and 30–60 days post-admission.

(D) Actin (ACTB;ACTG1) abundance in the sample closest to day 20 post-admission (D20^+/−) and the final plasma sample obtained from each participant grouped by survival outcome (survived: S, blue; deceased: D, pink).

(E) Average, maximum, D20^+/−, and final plasma ORM1;ORM2 per participant grouped by survival outcome.

(F) Fitted linear regression per participant of the correlation obtained from the values for ORM1;ORM2 and actin (ACTA2;ACTB;ACTG1) (left) and violin plot of the corresponding slopes (right).

(G) Correlation between the final values for ORM1;ORM2 and actin (ACTB;ACTG1) per participant who either survived (gray circles) or died (red circles).

(H) Difference between the final and longitudinal maximum ORM1;ORM2 abundance segregated by the corresponding longitudinal average actin values above (red circles) or below (gray circles)150 RPA per participant.

(I) Correlation between the actin and CRP abundance in the final plasma sample collected from each participant (left) or between the longitudinal average ORM1;ORM2 and CRP values (right).

(J) Correlation between the average ORM1;ORM2 and the final HI readings (left). Difference between the final and minimum HI values per participant segregated by whether their final ORM1;ORM2 values were above or below 30,000 RPA (right).

(K) Correlation between longitudinal maximum actin and FGG values.

(L) Longitudinal maximum D-dimer readings in participants with maximum ORM1;ORM2 values above or below 43,000 RPA (right).

(M) Probability of survival in CP clusters according to the longitudinal average values of ORM1;ORM2 (left) or the final actin values (right). Statistics by Mann-Whitney or Kruskal-Wallis test for single comparisons, one-way ANOVA for multiple comparisons, simple linear or non-linear regression for correlations, and Mantel-Cox survival analysis. See also Figure S4.